Ionis Reports Q3 2026 Revenue Growth Driven by DAWNZERA Amid TRYNGOLZA Launch Adjustments
Ionis Pharmaceuticals reported third-quarter revenue of $243 million, marking a significant year-over-year increase when excluding prior-year one-time payments. Commercial revenue rose 18% to $136 million, fueled by the strong performance of the DAWNZERA franchise, which saw sales grow 40% from the previous quarter due to increased patient adoption. Despite commercial momentum, the company lowered its full-year guidance for TRYNGOLZA to approximately $50 million, down from a previous range of $100-$110 million, citing a more gradual launch ramp. Consequently, Ionis has pushed its projected cash flow breakeven timeline back by one year to 2029, following Phase 3 setbacks and the slower-than-expected TRYNGOLZA rollout.
Topics: guidance revision pharmaceuticals product sales revenue growth